Cynthia A. Challener

Mass spectrometry and automation are growing in importance for protein characterization, but further improvements are still needed.

Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.

In a pandemic, genetic vaccines offer several advantages over traditional approaches.

Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.